In colon cancer, MDM2 amplification or higher transcript abundance is associated with lower metastasis occurrence rates [18, 19], while in prostate and breast cancer, elevated MDM2 expression correlates with poor outcome [20, 21]. Here, MDM2 is linked to colonic neoplasm.